 |
|
|
| |
Use of long-acting Cabotegravir and Rilpivirine in a real-life setting: 12-month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH-NA Cohort-France
|
| |
| |
M. Hessamfar1,2, O. Leleux2, A. Peyrouny-Mazeau2, C. Krzyzanowsky1, G. Le Moal3, D. Neau4, H. Ferrand5, A. Desclaux4, E. Lazaro6, P. Duffau7, Y. Gérard8, M-A Vandenhende9, F. Bonnet1,2.
|
| |
|
|
|
|
|
